We investigated the survival benefit of pulmonary resection for patients with multidrug-resistant tuberculosis. To weigh the survival benefit of pulmonary resection for patients with multidrug-resistant tuberculosis who have undergone surgical treatment combined with medical chemotherapy compared with medical chemotherapy alone, we did a meta-analysis of available studies containing a hazard ratio for pulmonary resection. Among 1726 articles, 6 clinical reports, with a mean sample size of 47 patients per report, met the inclusion criteria. The pooled hazard ratio of 0.68 with a 95% confidence interval of approximately 0.44-1.07 suggested that the survival benefit of surgical pulmonary resection combined with chemotherapy, in a comparison of the groups 'with surgery' and 'without surgery', is not significantly greater than that of chemotherapy alone. Selection bias, due to the absence of rigid predetermined indications for pulmonary resection, limited the validity of this analysis. Due to the heterogeneity of the patient groups, greater attention is required to compute additional hazard ratios in future studies with stratification of factors such as cardiopulmonary functions, disease extent and the presence of a cavity. These additional computations in future studies are necessary to determine the survival benefit and to support the rigid surgical indications.
INTRODUCTION
Pulmonary tuberculosis (TB) remains a major global health problem [1] . Most patients with drug-susceptible TB can be treated by a combination of isoniazid, rifampicin, pyrazinamide and ethambutol [2] . Multidrug-resistant tuberculosis (MDR-TB) is resistant to isoniazid and rifampicin [3] ; extensive drug-resistant tuberculosis (XDR-TB) is MDR-TB with additional resistance to all fluoroquinolones and at least one of the second-line drugs such as amikacin, capreomycin or kanamycin [4] .
MDR-TB or XDR-TB requires extended treatment and potentially toxic drug regimens, which often result in more treatment failures and higher death rates [5] . Thus, ever since Pomerantz et al. [6] reported in 1991 the success of surgical treatment combined with medical chemotherapy, pulmonary resections for MDR-TB have been performed and the reported treatment outcomes have improved [7] [8] [9] [10] . Pulmonary resection is indicated for the management of drug-resistant forms of TB [11, 12] , and selective removal of the pulmonary cavities that harbour TB organisms has been presumed to benefit the outcome [13] . Nonetheless, the role of surgical pulmonary resection has been controversial and not properly established [14, 15] . Therefore, in consideration of a previous meta-analysis by Xu et al. on surgical treatment success rates for patients with MDR-TB [16] , the goal of the present study is to provide an additional perspective by comparing the survival benefit of pulmonary resection for the patients who have had surgical treatment combined with medical chemotherapy, compared to that for the patients who have had chemotherapy alone.
MATERIALS AND METHODS

Identification of studies
We conducted a systematic electronic search of the literature for articles published from 1981 to 2015 inclusively to evaluate the effects of pulmonary resection on the survival outcomes of patients with MDR-TB. We searched the US National Library of Medicine's PubMed database, EMBASE and the Cochrane Central Register of Controlled Trials. The key search terms in the title or abstract were tuberculosis, TB, MDR, XDR, drug resistant, drugresistant, multidrug, multi-drug, multidrug-resistant, extensively, outcome and cohort, in consideration of prior pilot searches described in Supplementary Material.
All relevant articles were evaluated using the predefined selection and exclusion criteria. Two investigators (H.F.R. and J.K.) performed the search independently, extracting the following data from each study and reviewing each retrieved article: (i) first author and year of publication and (ii) any relevant information that could be used directly or used indirectly to compute hazard ratios (HRs) and their standard errors (SEs) [17] . Discrepancies between the 2 reviewers were resolved through discussion. The final results were reviewed by the senior investigators (S.H.N. and J.M.K.). If the required information was unavailable in the relevant articles, no request was sent to the corresponding author for additional data.
Eligibility criteria, quality assessment and bias
The criteria for eligibility of a study to be included in the metaanalysis were as follows: (i) an original article published in English from 1981 to 2015 inclusively; (ii) the original article must address an association between pulmonary resection and treatment outcome for MDR-TB in humans; (iii) each original article must report an HR with a confidence interval for pulmonary resection in patients with MDR-TB or sufficient data for estimating HR with a 95% confidence interval (CI).
Only studies that met quality assessment criteria were included for analysis. Studies should be case controlled, retrospective, prospective or randomly controlled in design, with basic demographic information. When more than 1 study was based on the same population, only the most recent study was included in the analysis. In reference to the exclusion criterion of the previous meta-analysis [16] , only studies including > _10 patients were selected for inclusion.
Publication bias was illustrated visually by a funnel plot, followed by Begg's test [18] and Egger's test [19] , which are, respectively, based on rank correlation and on weighted linear regression, in order to assess potential publication bias.
Statistical analysis
The meta-analysis for all statistical analyses was performed using R with a package 'meta'; funnel plot asymmetry was measured by the package 'rmeta'. The PRISMA checklist was used as the protocol for the meta-analysis according to its guidelines [20] . The Cochrane v 2 test and the measure of inconsistency (I 2 ) were used to evaluate the heterogeneity across studies, where the I 2 statistic >50% was taken to indicate heterogeneity. To assess the strength of association, we used the HR and its 95% CI. Pooled estimates were calculated with the fixed-effect model (Mantel-Haenszel method) if there was no significant aforementioned heterogeneity; otherwise, we used the random-effect model (DerSimonianLaird method). However, if substantial heterogeneity in the patient populations and study designs is observed, one may consider using the random-effect model instead.
Despite a sufficient and ever-growing number of original articles on survival analysis outcomes, not all relevant publications reported the HR associated with pulmonary resection, which is required for a meta-analysis including the KaplanMeier curve [21] . The most accurate method of obtaining HRs and 95% CIs for computation is to retrieve the reported HR and its 95% CIs directly from the studies: SE of log e HR ð Þ= log e upper limit of CI ð Þ -log e lower limit of CI ð Þ 2 Â 1:96 .
If this information was not directly available, we used various methods of calculating those values from other reported parameters [22] . When only survival curves were available, this curve was used instead to reconstruct the HR and its variance, with the assumption that the patient censor rate was constant during the study follow-up period, per popular methods proposed by Parmar et al. [17] . We used digitizing software, DigitizeIt [23] , for data extraction from survival curves and Tierney's Excel spreadsheet [24] for Parmar's method, respectively. All-cause mortality has been assumed, if not stated explicitly.
RESULTS
Literature search
As illustrated in Fig. 1 , our search strategy comprised identification of 2960 studies (1260 from PubMed, 1694 from EMBASE and 6 from Cochrane) regarding MDR-TB. After removing the duplicate articles in the EMBASE database that were also in the PubMed database, a total of 1726 studies (1260 PubMed studies, 460 EMBASE studies and 6 Cochrane studies) were examined.
After examination of the titles, abstracts and full texts, 6 published studies [25] [26] [27] [28] [29] [30] met all inclusion criteria and were included in this meta-analysis. After applying the exclusion criteria for managing selection bias [16] , 2 studies in which the number of patients was less than 10 were excluded [31, 32] . Three articles [28, 33, 34] reported the HR on surgical treatment on the same cohort; therefore, after excluding 1 article due to the confounding effect of diabetes mellitus [33] , the most recent article [28] of the remaining articles was chosen for the meta-analysis. Table 1 lists the characteristics of all of the retrospective studies [25] [26] [27] [28] [29] [30] that compared the effects of resection with chemotherapy versus chemotherapy alone with respect to univariate analysis of all-cause mortality. Three studies of patients with MDR-TB [25] [26] [27] and 3 studies of patients with MDR-TB or XDR-TB [28] [29] [30] were selected for inclusion in the analysis. Among these studies, 3 studies were performed in Asian-dominant countries [27] [28] [29] , and 3 studies were performed in White-dominant countries [25, 26, 30] . The length of the follow-up period after pulmonary resection varied from 2 to 11 years. The mean sample size for the patients who had operations was computed to be 47 patients per report (range 18-76). Four studies [26, [28] [29] [30] reported the HRs of pulmonary resection, whereas 2 studies [25, 27] 
Study characteristics
Heterogeneities and random-effects model
We noted a substantial heterogeneity in the patient populations and study designs: Frequently cited factors in relation with the outcome of surgical treatment included alcohol consumption [35, 36] , the presence of a cavity [35, 36] , the proportion of patients with XDR-TB [4] and HIV co-infection [35] [36] [37] [38] . In addition, the outcome of surgical treatment may be affected by diabetes Figure 1 : Schematic representation of the study selection process. In our previous pilot studies, provided as Supplementary Material, we found that the survival benefit of pulmonary resection was not the main objective of some eligible studies. Therefore, it was difficult to determine confidently whether to exclude studies based only on title and abstract without checking necessary information about the hazard ratios for pulmonary resection, i.e. in the tables or survival curves. Additionally, to codify the procedures and to lower the subjectivity of ambiguous studies between the first 2 authors during the screening, we inevitably performed a full-text search, whenever possible, in order to extract information necessary to compute the HR. Due to language problems, all studies not published in English were excluded. Chan et al. divided patients into 2 mutually exclusive groups, such that, unlike the patients with 'non-extensive disease' of Study ID-1, the patients with 'extensive disease' of Study ID 1-2 are determined radiologically when the combined cavity diameters are > _15 cm or moderately dense infiltrates are > _75% of the lung fields. b HRs are computed from survival curves [25, 27 ] using Parmar's method [17] . MDR and XDR are, respectively, the acronyms that stand for 'multidrug-resistant' and 'extensively drug-resistant', which describe properties of tuberculosis. MDR-TB is resistant to the antituberculosis drugs isoniazid and rifampicin, whereas XDR-TB is MDR-TB with additional resistance to all fluoroquinolones and at least one of the second-line drugs such as amikacin, capreomycin or kanamycin. HR represents the relative risk of the treatment based on the comparison of event rates. "SE represents the standard deviation of the sampling distribution with respect to a statistic. CI is used as an interval estimate of a population parameter.
[33]; lung cancer [39] ; pneumothorax [40] ; and the extent of resection, such as wedge resection, segmentectomy, lobectomy, bilobectomy and pneumonectomy [25, 32, [41] [42] [43] [44] . No efforts by the included studies were identified to control for these factors with respect to the groups 'with surgery' and 'without surgery'. To accommodate the heterogeneous patient groups, we used the random-effects model, although the fixed-effects model may be indicated because I 2 was below 50% and we were unable to reject the null hypothesis of homogeneity. Figure 2 illustrates a forest plot for the meta-analysis of HRs, in order to investigate the survival benefits of pulmonary resection in patients with MDR-TB. This random-effects model with a pooled HR of 0.68 [95% CI 0.44-1.07] suggests that one cannot conclude from these results that it is less hazardous to receive pulmonary resection.
Treatment outcomes
Publication bias
As illustrated in Fig. 3 , due to symmetrical distribution around log e (0.68) of the funnel plot in relation to Fig. 2 , there does not appear to be any strong evidence of publication bias from either Begg's test (P = 0.453) or Egger's test (P = 0.554). Additionally, since the main objective of the referenced articles was not solely to determine the better survival outcomes by surgery, a publication bias due to the lack of negative results with respect to worse surgical treatment outcomes itself would be less likely to have influenced the pooled HR result.
DISCUSSION
The present study (Fig. 2) concludes that, compared with chemotherapy alone, the survival benefit of pulmonary resection combined with chemotherapy is not significant. Two major limitations that raised concern are as follows: (i) 'no rigid criteria for selection or exclusion for surgery' [25] and (ii) heterogeneity of patient groups. These aspects impose limitations not only on the results of the present study but also possibly on the results of future studies and other meta-analyses in support of the necessity for pulmonary resection and for defining its rigid surgical indications. Thus, the limitations are followed by our preliminarily suggestions.
The lack of rigid surgical indications inevitably leads to reliance on 'expert opinion' regarding whether to proceed with pulmonary resection [45] [46] [47] , thus rendering the inclusion of patients from each institution highly selective and variable. Even when one applies the exclusion criteria to remove small studies vulnerable to selection bias [16] , the intrinsic, systemic error for selection bias that results because surgeons select patients based on experience still remains an issue. Therefore, it is acknowledged that the significance of the results of the forest plot should be greatly diminished due to the lack of rigid surgical indications.
As mentioned earlier, the patient groups 'with surgery' and 'without surgery' are heterogeneous. Overall, the patient group 'with surgery' can be considered to consist of the 'healthier' patients who have been biasedly selected for surgery [46] and patients who are refractory to the chemotherapy and thus receive salvage operations in the later course of the disease. The patient group 'without surgery' can be presumed to include patients with and without an excessively insufficient cardiopulmonary function to endure surgical treatment [27, 48] . The proportion of the patients in the late course of disease or of patients with insufficient cardiopulmonary function presumably affects the survival analysis outcome. Due to the heterogeneity of the patient groups, the conventional hazard ratios for the patient groups 'with surgery' and 'without surgery' may not be optimized to unleash the survival benefit of pulmonary resection, assuming that there is, in fact, a survival benefit.
We therefore propose to report the following hazard ratios in addition to the conventional hazard ratio, HR conventional . For example, to investigate the survival benefit of pulmonary resection in consideration of insufficient cardiopulmonary function to tolerate surgery, the HRs between 'with surgery' and 'without surgery' can be recomputed with the stratification of insufficient cardiopulmonary function, HR cardiopulmonary_function . Similarly, after the stratification of other factors, such as presence of cavity, extent of resection, whether MDR-TB or XDR-TB, and other comorbidities, such as diabetes, HIV and cancer, the HRs can be recomputed using the given study data sets. These additional HRs of future studies will be used to determine when to operate on patients with MDR-TB; consequently, another later metaanalysis of this accumulated statistical evidence will support the use of rigid surgical indications.
With respect to additional limitations, newly developed MDR-TB medications [49, 50] may improve the treatment success rate and HRs such that, after the accumulation of treatment outcomes in the future, the survival benefits of surgical treatments in addition to medical treatments may be diminished. In addition, all studies evaluating the effects of pulmonary effects on the survival outcomes were retrospective, with no comparison of the characteristics of the patients with and without surgery. Overall, we admit that 'the quality of data on the efficacy of adjunctive surgical therapy is relatively poor' [46] . Thus, one should be aware of the limitation of possible biases due to the unmeasured variables that could have affected the outcomes.
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